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ABSTRACT
Objectives To explore the utilisation of pharmacy- 
based sexual and reproductive health services (SRHS) in 
order to optimise delivery and identify barriers to access.
Methods The health provider Umbrella offers six SRHS 
from over 120 pharmacies in Birmingham (England). In 
this retrospective study, data collected between August 
2015 and August 2018 were used to analyse uptake, 
user characteristics and attendance patterns according to 
day of the week.
Results A total of 60 498 requests for a pharmacy 
service were included in the analysis. Emergency 
contraception (50.4%), condoms (33.1%) and STI self- 
sampling kits (9.6%) accounted for more than 90% of all 
requests. A lower uptake of services was observed for the 
contraceptive injection (0.6%), oral contraception (5.4%) 
and chlamydia treatment (1.0%). Services were most 
likely to be requested by those self- identifying as female 
(85.6%), and those aged 16–24 years (53.8%). Based 
on available ethnicity data (n=54 668), most requests for 
a service were made by White/White British individuals 
(43.4%) and Asian/Asian British people (23.1%). The 
largest number of services were delivered on Mondays 
(20.9%) and the lowest on Sundays (5.0%). A high 
proportion of requests for services on Saturdays (57.0%), 
Sundays (67.6%) and Mondays (54.4%) were made by 
females presenting for emergency contraception.
Conclusion The evaluation of healthcare utilisation 
is important to help refine and optimise the delivery of 
services. However, information relating to pharmacy- 
based SRHS is scarce and often limited to a single type 
of service provision. Overall, a wide range of pharmacy- 
based services were accessed by a diverse range of 
people, suggesting that pharmacies are a suitable 
provider of many SRHS. However, the routinely collected 
data analysed in the study had several limitations 
restricting the analysis. Sexual health providers should 
ensure they collect data which are as comprehensive as 
is possible in order to help understand the utilisation of 
services.
INTRODUCTION
Cuts to National Health Service (NHS) sexual 
health budgets have led to the development of 
new service delivery pathways. Several countries 
including Australia, Canada, New Zealand and the 
USA have increasingly started to expand the use of 
pharmacies for healthcare delivery and the NHS in 
the UK has been at the forefront of expanding the 
role of pharmacy staff and services.1 While pharma-
cies in England have been providing limited sexual 
and reproductive health services (SRHS) for several 
years,2 primarily emergency contraception and chla-
mydia screening, they are now increasingly offering 
a wider variety of options, including the provision 
of: condoms, oral contraception, the contraceptive 
injection and screening/treatment for STIs.3 When 
provided via an NHS sexual health provider, these 
services are all free of charge to the user.
It is important to evaluate the utilisation of 
healthcare services to optimise delivery and identify 
barriers to access.4 However, to date, evidence on 
the utilisation of pharmacy- based SRHS is scarce 
and limited to single sexual health conditions or 
needs such as chlamydia screening and oral contra-
ception.5 6 This study is the first to analyse the utili-
sation of a large range of pharmacy- based SRHS 
using data collected over 3 years in Birmingham 
(England).
Our objectives were
 ► To describe the uptake of six SRHS encom-
passing contraception, and testing and treat-
ment for STIs.
 ► To describe the characteristics of those using 
pharmacy- based SRHS.
 ► To describe the attendance patterns of individ-
uals using pharmacy- based SRHS.
METHODS
Umbrella and their pharmacy-based SRHS
In August 2015, the sexual health provider in 
Birmingham (Umbrella)7 started to offer services 
through many community pharmacies. The services 
are funded by Birmingham’s local council and are 
free of charge to the user. Pharmacies which would 
like to provide Umbrella’s services have to fulfil 
certain criteria including having a private consul-
tation room. Overall, between August 2015 and 
August 2018, the number of community pharmacies 
in Birmingham (England) has decreased from 301 
to 285.8 Umbrella pharmacies can operate either at 
the ‘Tier 1’ level or the more comprehensive ‘Tier 
2’ level. Between August 2015 and August 2018, 
the number of pharmacies offering more exten-
sive Umbrella ‘Tier 2’ services increased from 18 
to 47, whereas the number of ‘Tier 1’ pharmacies 
decreased from 158 to 80. Hence, the total number 
of Umbrella pharmacies delivering SRHS decreased 
from 176 pharmacies to 127 between August 2015 
 o
n
 Septem
ber 1, 2020 by guest. Protected by copyright.
http://sti.bmj.com/
Sex Transm
 Infect: first published as 10.1136/sextrans-2020-054488 on 15 August 2020. Downloaded from
 
2 Gauly J, et al. Sex Transm Infect 2020;0:1–8. doi:10.1136/sextrans-2020-054488
Health services research
and August 2018. Pharmacies which decide to deliver the ‘Tier 
2’ level have to undergo more comprehensive pharmacy staff 
training compared with ‘Tier 1’ pharmacies. Training for both 
‘Tier 1’ and ‘Tier 2’ services is delivered by Umbrella’s education 
team.
Both ‘Tier 1’ and ‘Tier 2’ pharmacies provide condoms, emer-
gency contraception and STI self- sampling kits testing for chla-
mydia and gonorrhoea from available stock, which is dispensed 
directly to pharmacy users. While ‘Tier 1’ pharmacies can only 
provide women presenting for emergency contraception with 
one emergency contraceptive pill, ‘Tier 2’ pharmacies can 
provide women with two emergency contraceptive pills, one for 
immediate and one for future use (Advance EC). ‘Tier 2’ phar-
macies also provide the contraceptive injection, oral contracep-
tion, chlamydia treatment and comprehensive STI self- sampling 
kits (testing for chlamydia, gonorrhoea, syphilis and HIV, plus 
hepatitis B for men who have sex with men) from in store stock 
provided directly to pharmacy users. ‘Tier 1’ pharmacies do 
not have those comprehensive STI self- sampling kits in stock. 
However, comprehensive STI self- sampling kit can be pre- 
ordered on the Umbrella website and be collected at an Umbrella 
pharmacy of their choice (‘Tier 1’ or ‘Tier 2’ pharmacy). The 
comprehensive STI self- sampling kits are the only service that 
can be pre- ordered on the Umbrella website.
An overview of Umbrella’s pharmacy services and eligibility 
criteria is provided in table 1.
Study design
A retrospective analysis was performed to evaluate all SRHS 
requests made by users at Umbrella pharmacies between August 
2015 and August 2018.
Data collection
Data were available from two data sources: pharmacy electronic 
patient records (PharmOutcomes) and online patient question-
naires (collected via the Umbrella website).
When people attended for emergency contraception, oral 
contraception, contraceptive injection, condoms or chlamydia 
treatment, they were seen in a consultation room by pharmacy 
staff, who recorded demographic and clinical information on an 
electronic patient record (PharmOutcomes). Those who wanted 
to pre- order an STI self- sampling kit via the Umbrella website 
had to complete an online questionnaire and then collect the 
STI self- sampling kit from an Umbrella pharmacy of their choice 
Table 1 Overview of Umbrella’s pharmacy services, eligibility criteria, data source and characteristics analysed for this study
SRHS provided Pharmacy ‘tier’ Eligibility by gender Eligibility by age Data source
Associated data included in 
this analysis
Emergency Contraception Tier 1 and Tier 2 Females 13–60 Pharmacy Electronic Patient Record 
(PharmOutcomes)
 ► Age
 ► Gender
 ► Ethnicity
 ► Weekday of attendance
Advance Emergency 
Contraception
Tier 2 Females 13–60 Pharmacy Electronic Patient Record 
(PharmOutcomes)
 ► Age
 ► Gender
 ► Ethnicity
 ► Weekday of attendance
Referral or Appointment for the 
copper coil at closest sexual 
health clinic
Tier 1 and Tier 2 Females 13–60 Pharmacy Electronic Patient Record 
(PharmOutcomes)
 ► Age
 ► Gender
 ► Ethnicity
 ► Weekday of attendance
Oral Contraception Tier 2 Females 13–60 Pharmacy Electronic Patient Record 
(PharmOutcomes)
 ► Age
 ► Gender
 ► Ethnicity
 ► Weekday of attendance
Contraceptive Injection Tier 2 Females 13–60 Pharmacy Electronic Patient Record 
(PharmOutcomes)
 ► Age
 ► Gender
 ► Ethnicity
 ► Weekday of attendance
Condoms Tier 1 and Tier 2 Females and males ≥13 Pharmacy Electronic Patient Record 
(PharmOutcomes)
 ► Age
 ► Gender
 ► Ethnicity
 ► Weekday of attendance
Collection of pre- ordered STI 
self- sampling kits testing for up 
to five STIs
Tier 1 and Tier 2 Females and males ≥16 Online Patient Questionnaire (Umbrella website)  ► Age
 ► Gender
 ► Weekday of attendance
STI self- sampling kits testing for 
up to five STIs
Tier 2 Females and males ≥16 Pharmacy Electronic Patient Record 
(PharmOutcomes)
Until 6 Feb 2018 and Pharmacy Online Patient 
Questionnaire (Umbrella website) from 7 Feb 
2018 onwards
 ► Age
 ► Gender
 ► Weekday of attendance
Chlamydia and Gonorrhoea STI 
self- sampling kit supplied to 
women presenting for emergency 
contraception
Tier 1 and Tier 2 Females 15–24 Pharmacy Electronic Patient Record 
(PharmOutcomes)
until 6 Feb 2018 and Online Patient 
Questionnaire (Umbrella Website) from 7 Feb 
2018 onwards
 ► Age
 ► Gender
 ► Weekday of attendance
Chlamydia Treatment Tier 2 Females and males ≥13 Pharmacy Electronic Patient Record 
(PharmOutcomes)
 ► Age
 ► Gender
 ► Ethnicity
 ► Weekday of attendance
SRHS, sexual and reproductive health services.
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(‘Tier 1’ or ‘Tier 2’ pharmacy). Data from individuals who were 
provided with an STI kit from a pharmacy without pre- ordering 
were collected in PharmOutcomes before 6 February 2018, and 
via the Umbrella website thereafter.
Each user of an Umbrella pharmacy service was automatically 
assigned a Patient Identification Number (ID). If a user returned 
to the same pharmacy to use the Umbrella service again, this was 
registered under the original patient ID. However, if a pharmacy 
user subsequently visited a different Umbrella pharmacy, this was 
recorded under a new patient ID. Hence, since users could have 
been recorded under different patient IDs it was not possible to 
evaluate frequency of attendance for individual patients.
If a pharmacy user used more than one of the ‘Tier 1’ or ‘Tier 
2’ services (eg, emergency contraception and condoms), this was 
recorded as separate requests. It was therefore not possible to 
evaluate whether multiple services were delivered at a single 
attendance or over several pharmacy visits.
Service users self- assigned their demographic information: 
ethnicity, age and gender. When asked for their gender, users 
had the possibility to self- identify as female, male or transgender. 
Ethnicity data were collected consistently for all services except 
the STI self- sampling kits. Inconsistencies in the data collection 
meant that it was not possible to analyse ethnicity data on STI 
self- sampling kits, specifically no ethnicity data were collected 
until March 2017 and subsequently different ethnic group cate-
gories were used. Ethnicity data were therefore only analysed 
for individuals accessing emergency contraception, oral contra-
ception, contraceptive injection, condoms and chlamydia 
treatment.
User activity recorded on PharmOutcomes and the STI website 
were combined into a single data set and re- coded where neces-
sary. The data set included:
 ► PharmOutcomes data on all user requests recorded for 
emergency contraception, oral contraception, contraceptive 
injection, chlamydia treatment, condoms between August 
2015 and August 2018.
 ► PharmOutcomes data (recorded between August 2015 and 
the sixth February 2018) and STI Website data (recorded 
between 7 February 2018 and August 2018) on all STI self- 
sampling kits that were provided directly to users
 ► STI Website data on all STI self- sampling kits that were 
ordered online and collected from a pharmacy between 
August 2015 and August 2018
An overview of the data sources and the characteristics anal-
ysed by SRHS is presented in table 1.
Inclusion criteria
Only those service records which met Umbrella’s eligibility 
criteria outlined in table 1 were included in the analysis.
Data analysis
A descriptive analysis, count and percentage for categorical char-
acteristics and range and median (IQR) for continuous charac-
teristics, was conducted using IBM SPSS V.24 to evaluate:
 ► Uptake: the total number of requests for each SRHS.
 ► User characteristics: age, gender and ethnicity; age distribu-
tion by gender; ethnicity distribution by gender.
 ► Attendance pattern: the number of services provided by 
the pharmacy according to the day of the week and type of 
SRHS. For those users who pre- ordered an STI kit online, 
the weekday that the kit was collected rather than pre- 
ordered was analysed.
RESULTS
In total, 60 498 data entries were included in the analysis. An 
overview of the service uptake, service user demographics and 
attendance patterns by the day of the week is provided in table 2. 
Information on the age- distribution, ethnicity- distribution and 
weekday of service received by gender can be found in table 3.
Service use
Emergency Contraception (50.4%), condoms (33.1%) and STI 
self- sampling kits (9.6%) accounted for more than 90% of all 
service requests. The contraceptive injection was least frequently 
requested (0.6%), with oral contraception (5.4%) and chlamydia 
treatment (1.0%) also being used at relatively low levels.
Demographic characteristics
Gender
For the services available to all sexes, people recorded as female 
accounted for the majority of requests: condoms (females: 
66.4% vs males: 33.1%), STI self- sampling kits (females: 69.4% 
vs males: 30.5%) and chlamydia treatment (females: 64.6% vs 
males: 34.9%). Fifteen people recorded as transgender used the 
service over the 3- year study period (<1%).
Age
People in the age group 16 to 24 years accounted for more 
than 50% of all requests. For all services consistently, females 
and males 16–24 years old accounted for the largest number 
of service requests. The median age across all services was 24 
years (IQR 20–30). The median age was lowest for users who 
requested an STI kit (21 years old (IQR 20–27)) and highest for 
EC (25 years old (IQR 20–29)).
Ethnicity
As mentioned in the methods section, ethnicity data were not 
available for pharmacy users who requested an STI self- sampling 
kit (n=5830/60 498) due to inconsistencies in the data collection.
Based on data on the remaining 54 668 service requests, 
White/White British individuals were the largest group who 
accessed pharmacy services (43.3%), followed by Asian/Asian 
British (23.1%), Black/Black British (15.1%), mixed (6.4%) and 
other ethnic groups (2.0%).
Attendance patterns by day of week
All services except the contraceptive injection and chlamydia 
treatment were most frequently accessed on Monday, which was 
the most common day to present in a pharmacy for a SRHS overall 
(20.9%). The uptake of services on a Saturday (12.2%) and 
Sunday (5.0%) was lower. The majority of requests on Saturday 
(57.0%), Sunday (67.6%) and Monday (54.4%) were made by 
women presenting for emergency contraception. Females were 
most likely to request emergency contraceptive, condoms and 
STI self- sampling kits on Mondays, and chlamydia treatment 
and the contraceptive injection on Wednesday. In contrast, males 
were most likely to obtain condoms and chlamydia treatment on 
Fridays and STI self- sampling kits on Tuesdays.
DISCUSSION
Summary of the main findings
A large number of requests for sexual health related care deliv-
ered via pharmacies were made over a 3- year period. As might 
be expected, there was a higher level of provision for certain 
services (emergency contraception, condoms, STI self- sampling 
kits), which were available in all Umbrella pharmacies (between 
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Table 3 Distribution of age, ethnicity and weekday accessed by gender
Gender Service Age group Frequency (%) Ethnicity Frequency (%) Weekday of attendance Frequency (%)
Females Emergency contraception 
(n=30 464)
13–15 267 (0.9) White/White British 12 380 (40.6) Monday 6893 (22.6)
16–19 6223 (20.4) Asian/Asian British 7475 (24.5) Tuesday 4951 (16.3)
20–24 10 734 (35.2) Black/Black British 4964 (16.3) Wednesday 4223 (13.9)
25–29 6208 (20.4) Mixed/Multiple ethnic groups 2133 (7.0) Thursday 4040 (13.3)
30–39 5713 (18.8) Other ethnic groups 571 (1.9) Friday 4119 (13.5)
40+ 1319 (4.3) Unknown 2941 (9.7) Saturday 4203 (13.8)
  Sunday 2035 (6.7)
Oral contraception 
(n=3245)
13–15 19 (0.6) White/White British 1917 (59.1) Monday 599 (18.5)
16–19 541 (16.7) Asian/Asian British 449 (13.8) Tuesday 587 (18.1)
20–24 1156 (35.6) Black/Black British 427 (13.2) Wednesday 505 (15.6)
25–29 644 (19.8) Mixed/Multiple ethnic groups 173 (5.3) Thursday 585 (18.0)
30–39 608 (18.7) Other ethnic groups 50 (1.5) Friday 591 (18.2)
40+ 277 (8.5) Unknown 229 (7.1) Saturday 293 (9.0)
  Sunday 85 (2.6)
Contraceptive injection 
(n=359)
13–15 – White/White British 159 (44.3) Monday 46 (12.8)
16–19 43 (12.0) Asian/Asian British 33 (9.2) Tuesday 63 (17.5)
20–24 117 (32.6) Black/Black British 67 (18.7) Wednesday 73 (20.3)
25–29 85 (23.7) Mixed/Multiple ethnic groups 18 (5.0) Thursday 71 (19.8)
30–39 84 (23.4) Other ethnic groups 19 (5.3) Friday 63 (17.5)
40+ 30 (8.4) Unknown 63 (17.5) Saturday 37 (10.3)
  Sunday 6 (1.7)
Condoms (n=13 286) 13–15 109 (0.8) White/White British 6425 (48.4) Monday 2777 (20.9)
16–19 2427 (18.3) Asian/Asian British 2923 (22.0) Tuesday 2343 (17.6)
20–24 4370 (32.9) Black/Black British 1755 (13.2) Wednesday 2145 (16.1)
25–29 2227 (16.8) Mixed/Multiple ethnic groups 825 (6.2) Thursday 2122 (16.0)
30–39 3132 (23.6) Other ethnic groups 217 (1.6) Friday 2083 (15.7)
40+ 1021 (7.7) Unknown 1141 (8.6) Saturday 1435 (10.8)
  Sunday 381 (2.9)
STI self- sampling kits 
(n=4044)
13–15 – White/White British NA Monday 779 (19.3)
16–19 886 (21.9) Asian/Asian British NA Tuesday 699 (17.3)
20–24 1847 (45.7) Black/Black British NA Wednesday 559 (13.8)
25–29 656 (16.2) Mixed/Multiple ethnic groups NA Thursday 578 (14.3)
30–39 480 (11.9) Other ethnic groups NA Friday 693 (17.1)
40+ 175 (4.3) Unknown NA Saturday 513 (12.7)
  Sunday 223 (5.5)
Chlamydia treatment 
(n=382)
13–15 – White/White British 203 (53.1) Monday 56 (14.7)
16–19 96 (25.1) Asian/Asian British 13 (3.4) Tuesday 52 (13.6)
20–24 179 (46.9) Black/Black British 63 (16.5) Wednesday 71 (18.6)
25–29 73 (19.1) Mixed/Multiple ethnic groups 39 (10.2) Thursday 69 (18.1)
30–39 27 (7.1) Other ethnic groups 5 (1.3) Friday 68 (17.8)
40+ 7 (1.8) Unknown 59 (15.4) Saturday 57 (14.9)
  Sunday 9 (2.4)
Males Condoms (n=6610) 13–15 187 (2.8) White/White British 2550 (38.6) Monday 1146 (17.3)
16–19 1261 (19.1) Asian/Asian British 1670 (25.3) Tuesday 1153 (17.4)
20–24 1630 (24.7) Black/Black British 951 (14.4) Wednesday 1102 (16.7)
25–29 730 (11.0) Mixed/Multiple ethnic groups 283 (4.3) Thursday 1189 (18.0)
30–39 1373 (20.8) Other ethnic groups 211 (3.2) Friday 1277 (19.3)
40+ 1429 (21.6) Unknown 945 (14.3) Saturday 577 (8.7)
  Sunday 166 (2.5)
STI self- sampling kits 
(n=1781)
13–15 – White/White British NA Monday 323 (18.1)
16–19 243 (13.6) Asian/Asian British NA Tuesday 348 (19.5)
20–24 686 (38.5) Black/Black British NA Wednesday 268 (15.0)
25–29 378 (21.2) Mixed/Multiple ethnic groups NA Thursday 266 (14.9)
30–39 285 (16.0) Other ethnic groups NA Friday 274 (15.4)
40+ 189 (10.6) Unknown NA Saturday 205 (11.5)
  Sunday 97 (5.4)
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127 and 176 pharmacies between August 2015 and August 
2018), compared with other services (oral contraception, contra-
ceptive injection, chlamydia treatment) which were restricted to 
a limited number of pharmacies (between 18 and 47 pharmacies 
between August 2015 and August 2018).
Those self- identifying as female comprised the large majority 
of requests. Those between the ages of 16 and 24 accounted for 
more than 50% of requests. Most requests, for which ethnicity 
data were available, were made by those recorded as White/
White British and Asian/Asian British. Monday was the most 
common day to present, whereas Saturday and Sunday were the 
days with lowest attendances. The majority of service requests 
occurring at the weekend and on Monday, were made by women 
presenting for emergency contraception.
Comparison with existing literature
Attendance patterns by gender varied and it was found that emer-
gency contraception, condoms and STI self- sampling kits were 
most commonly requested on Mondays. It is likely that women 
requesting emergency contraception are also offered condoms 
and STI self- sampling kits by pharmacy staff when they attend. 
This would suggest that the concept of integrated services, where 
several services are provided in one visit, is working. Males 
appear to obtain condoms before the weekend, possibly because 
sexual intercourse is more likely to occur at the weekend.9
Our analysis found that pharmacy- based SRHS accessible to 
both sexes were used less frequently by those self identifying as 
male than female, which is consistent with previous studies that 
reported a lower proportion of males attending for STI testing in 
a community pharmacy setting.6 10 This could indicate a barrier 
for male pharmacy- based SRHS access, possibly linked to the 
high proportion of female support staff in pharmacies.11 Males 
report a preference for having a consultation with a male health 
provider12 and having to approach female staff for SRHS might 
act as a deterrent.13 However, males are generally less likely than 
females to attend for healthcare14 and several studies have shown 
that males are also less likely than females to access STI testing 
in other settings, including primary care,15 sexual health clinics16 
and commercial venues.17 Males also have a lower uptake of 
self- sampling based STI testing,18 and less frequently order STI 
kits online16 19 or return STI kits sent to their homes.20–22 This 
suggests that the reduced use of sexual health services observed 
in males is not specific to pharmacies and indicates a need for 
further research to investigate the reasons for this and how best 
to address it.23
We only analysed STI self- sampling kits that were provided 
through Umbrella pharmacies whereas a recent study analysed 
the utilisation of Umbrella’s clinic- based STI testing and 
online STI self- sampling kits that were sent to people’s homes 
or collected at the clinic. We found that only one transgender 
person was provided with an STI kit through the pharmacy 
over 3 years; in contrast, the online testing based study found 
14 transgender people pre- ordered an STI kit to their home or 
to a clinic, and 26 transgender people were provided with STI 
screening at the clinic within a 6- month period.16 A recent study 
found that community pharmacists felt that discrimination and 
lack of provider knowledge were identified as barriers to phar-
macies for transgender people, and the low uptake of services 
by transgender people may support this finding.24 However, it is 
also possible that transgender people may have been incorrectly 
recorded as female or male and therefore not have been captured 
in our data set.
Based on the available ethnicity data, ethnic groups using SRHS 
in pharmacies were represented approximately in proportion to 
their prevalence in the local population25—White/White British 
(census 57.9% cf. study population 43.4%), Asian/Asian British 
(census 23.7% cf. study population 23.1%), Black/Black British 
(census 7.2% cf. study population 15.1%), Mixed/Mixed British 
(census 4.4% cf. study population 2.0%) and other ethnic groups 
(census 6.7% cf. study population 5.8%). Black/Black British 
appeared to be over- represented in comparison with the local 
population, suggesting that pharmacies may reach those associ-
ated with potentially poor sexual health outcomes.26 However, 
available data identified the number of service requests rather 
than the number of individual patients so this should be inter-
preted with caution.
Young people are particularly vulnerable to poor sexual 
health outcomes.27 Our data showed that people in the age 
group from 16 to 24 years old made up the majority of service 
requests and indicates that pharmacies have the potential to 
reach young people who are in high need for SRHS. Further, 
a higher proportion of those attending for STI screening were 
aged 16–24 in pharmacies compared with sexual health clinic 
attendees (3365/5530 (62.9%)) cf. 9654/19193 (50%)),16 
suggesting that pharmacy- based STI testing is acceptable to this 
demographic.
In line with other studies, we found that the total number of 
emergency contraception requests was highest on Mondays and 
lowest on Sundays.28 29 This may reflect difficulties in accessing 
pharmacies on Sundays, as a result of variable pharmacy hours, 
closure or unavailability of trained staff. According to data 
provided by Umbrella, the majority of Umbrella pharmacies 
(76.7%, 122/159) are closed on Sunday, suggesting that limited 
Sunday access was the reason for the low uptake of services. 
However, retrospective data on opening times are not available 
and these opening times may have differed in the past. Limited 
availability is a concern because emergency contraception is 
more effective when taken earlier after unprotected sex28 29 
suggesting that more research is required to explore the impact 
of limiting access.
Gender Service Age group Frequency (%) Ethnicity Frequency (%) Weekday of attendance Frequency (%)
Chlamydia treatment
(n=206)
13–15 – White/White British 76 (36.9) Monday 25 (12.1)
16–19 23 (11.2) Asian/Asian British 16 (7.8) Tuesday 30 (14.6)
20–24 80 (38.8) Black/Black British 42 (20.4) Wednesday 30 (14.6)
25–29 54 (26.2) Mixed/Multiple ethnic groups 18 (8.7) Thursday 32 (15.5)
30–39 35 (17.0) Other ethnic groups 4 (1.9) Friday 41 (19.9)
40+ 14 (6.8) Unknown 50 (24.3) Saturday 40 (19.4)
  Sunday 8 (3.9)
*The distribution of age, ethnicity and weekday accessed was not provided for transgender people because the numbers for this group were too little.
NA, not available.
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Strengths and limitations
Although understanding healthcare utilisation is crucial to iden-
tify barriers to access, previous literature on the utilisation of 
pharmacy- based sexual health services is scarce and limited to 
the delivery of single sexual health services. This is the first 
study evaluating SRHS data collected over a prolonged period 
of time. A limitation of the study is that the uptake of services 
over time could not be analysed because the date of attendance 
was unavailable from the service provider. Another limitation 
of this study is that the findings are limited to a single health 
provider in Birmingham and relied on routinely collected data 
which limited the possible analyses. Missing data meant that the 
utilisation of STI self- sampling kits could not be described in 
terms of ethnicity and the lack of a reliable patient ID number 
prevented analysis at a patient level. Furthermore, transgender 
people might not have been identified as they may be recorded 
as female or male rather than transgender.
Our findings suggest that Umbrella’s novel pharmacy service, 
which encompasses more than 120 pharmacies serving a popula-
tion over 1 million people and including attendees from a wide 
range of ethnic backgrounds, can provide useful background 
information to those planning and delivering pharmacy services 
elsewhere.
Implications for practice and future research
Research into the reasons for variation in service uptake according 
to different days of the week would be useful to better under-
stand why this occurs. This might include analysis of pharmacies’ 
opening times and the time taken to access emergency contracep-
tion after intercourse.
Barriers to males accessing sexual health services and black 
people accessing pharmacy- based sexual health services also 
warrants further investigation. However, a main recommendation 
of this study is for sexual health providers to design systems which 
optimise efficient data collection to enable rigorous and compre-
hensive analysis. Data linkage to enable anonymised identification 
of sexual health service attendees across integrated sexual health 
services would allow an analysis of utilisation at the patient level 
and assist future evaluations. Further, accounting for both gender 
and sex in data collection would improve the quality analysis30 and 
should also be considered. Finally, research on whether the type of 
person using pharmacy- based SRHS reflects how and where those 
services were advertised is needed to understand the effectiveness 
of reaching certain demographics by advertisement.
Key messages
 ► This retrospective study is the first to describe the utilisation 
of a large range of pharmacy- based SRHS.
 ► Further exploration of the impact of limited Sunday access is 
needed.
 ► Barriers to males accessing sexual health services and 
barriers to Black/Black British people using pharmacy- based 
services need to be explored.
 ► Data collection that allows comprehensive and rigorous 
analysis of the utilisation of pharmacy- based SRHS should be 
implemented by sexual health providers.
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